Medicenna, a clinical stage immunotherapy company, is focusing on developing new versions of IL-2, IL-4, and IL-13 Superkines, and Empowered Cytokines™ (ECs) for cancer treatment. The company's lead IL4-EC, MDNA55, has completed a Phase 2b clinical trial for the treatment of rGBM, the most fatal form of brain cancer. It has demonstrated significant efficacy and obtained Fast-Track and Orphan Drug status. Medicenna's potential long-acting IL2 Superkine, MDNA11, is expected to be a best-in-class next-generation IL-2, with superior binding and a preference for cancer-killing effector T cells and NK cells. The drug is set to be ready for clinical trials in 2021.
Medicenna Therapeutics's ticker is MDNA
The company's shares trade on the TSX stock exchange
They are based in Toronto, Ontario
There are 1-10 employees working at Medicenna Therapeutics
It is medicenna.com
Medicenna Therapeutics is in the Healthcare sector
Medicenna Therapeutics is in the Biotechnology industry
The following five companies are Medicenna Therapeutics's industry peers: